| Source: |
| Type: enzyme |
| HK2 (Hexokinase 2) is an enzyme that plays a crucial role in glycolysis, the process by which cells convert glucose into energy. HK2 is a key regulatory enzyme in the glycolytic pathway, and it is primarily expressed in various tissues, including muscle, brain, and cancer cells. HK2 has been shown to be overexpressed in many types of tumors, including breast, lung, and colon cancer. This overexpression may contribute to the development and progression of cancer by promoting glycolysis and energy production in cancer cells. HK2 is a key regulatory enzyme in the glycolytic pathway. HK2 plays a role in the regulation of glucose metabolism in diabetes. HK2 is involved in the regulation of cell proliferation, apoptosis, and autophagy. HK2 Inhibitors: -2DG -Curcumin -Resveratrol -EGCG -Berberine -Methyl Jasmonate (MJ) -Honokiol |
| Hepatocellular Carcinoma |
| 2424- | 2DG, | SRF, | The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells |
| - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 5269- | 3BP, | The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models. |
| - | in-vitro, | HCC, | NA |
| 938- | Api, | doxoR, | Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells |
| - | vitro+vivo, | HCC, | HepG2 |
| 2709- | BBR, | Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α |
| - | in-vitro, | HCC, | HepG2 |
| 1143- | CHr, | Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2 |
| - | in-vitro, | HCC, | HepG2 | - | in-vivo, | NA, | NA | - | in-vitro, | HCC, | HepG3 | - | in-vitro, | HCC, | HUH7 |
| 2422- | EMD, | Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by 1H NMR Based Metabolic Profiling |
| - | in-vitro, | HCC, | HepG2 |
| 2396- | PACs, | PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | L02 |
| 2421- | PB, | Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vivo, | NA, | NA | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | Nor, | L02 |
| - | in-vitro, | HCC, | HepG2 |
| 2342- | QC, | Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway |
| - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vivo, | NA, | NA |
| 2439- | RES, | By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | Nor, | L02 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:10 Cells:% prod#:% Target#:773 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid